OLD National Bancorp IN Invests $69,000 in Immix Biopharma, Inc. (NASDAQ:IMMX)

OLD National Bancorp IN bought a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $69,000. OLD National Bancorp IN owned approximately 0.05% of Immix Biopharma at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. Imprint Wealth LLC lifted its position in shares of Immix Biopharma by 49.4% during the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock worth $239,000 after purchasing an additional 11,400 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new position in Immix Biopharma in the third quarter valued at approximately $41,000. Finally, Commonwealth Equity Services LLC lifted its holdings in Immix Biopharma by 26.4% in the third quarter. Commonwealth Equity Services LLC now owns 28,855 shares of the company’s stock valued at $99,000 after buying an additional 6,030 shares during the period. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Price Performance

Shares of NASDAQ IMMX opened at $2.13 on Friday. The company’s 50 day simple moving average is $2.91 and its 200 day simple moving average is $4.03. Immix Biopharma, Inc. has a fifty-two week low of $1.40 and a fifty-two week high of $7.75. The firm has a market capitalization of $56.23 million, a P/E ratio of -2.39 and a beta of 0.05.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.24) earnings per share for the quarter. Sell-side analysts expect that Immix Biopharma, Inc. will post -0.91 EPS for the current fiscal year.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.